X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ADCOCK INGRAM (S. Africa) - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ADCOCK INGRAM
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ADCOCK INGRAM
Jun-14
NOVARTIS/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs758341-   
Low Rs579246-   
Sales per share (Unadj.) Rs228.4101.6-  
Earnings per share (Unadj.) Rs31.7-25.6-  
Cash flow per share (Unadj.) Rs32.8-21.2-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.179.7-  
Shares outstanding (eoy) m24.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.9 101.2%   
Avg P/E ratio x21.1-11.5 -183.4%  
P/CF ratio (eoy) x20.4-13.9 -147.3%  
Price / Book Value ratio x2.23.7 61.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,50549,605 33.3%   
No. of employees `0000.74.3 15.6%   
Total wages/salary Rs m1,4453,113 46.4%   
Avg. sales/employee Rs Th8,441.33,993.6 211.4%   
Avg. wages/employee Rs Th2,163.6725.2 298.3%   
Avg. net profit/employee Rs Th1,173.1-1,006.3 -116.6%   
INCOME DATA
Net Sales Rs m5,63917,144 32.9%  
Other income Rs m1,718120 1,431.2%   
Total revenues Rs m7,35717,264 42.6%   
Gross profit Rs m-63-2,971 2.1%  
Depreciation Rs m25740 3.4%   
Interest Rs m55464 11.9%   
Profit before tax Rs m1,575-4,055 -38.8%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792253 312.4%   
Profit after tax Rs m784-4,320 -18.1%  
Gross profit margin %-1.1-17.3 6.4%  
Effective tax rate %50.3-6.2 -804.2%   
Net profit margin %13.9-25.2 -55.1%  
BALANCE SHEET DATA
Current assets Rs m9,52212,557 75.8%   
Current liabilities Rs m3,2967,065 46.7%   
Net working cap to sales %110.432.0 344.7%  
Current ratio x2.91.8 162.5%  
Inventory Days Days37111 33.0%  
Debtors Days Days28124 22.9%  
Net fixed assets Rs m467,319 0.6%   
Share capital Rs m12380 155.0%   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,33613,456 54.5%   
Long term debt Rs m04,729 0.0%   
Total assets Rs m11,10525,420 43.7%  
Interest coverage x29.5-7.7 -381.3%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.7 75.3%   
Return on assets %7.6-15.2 -49.8%  
Return on equity %10.7-32.1 -33.3%  
Return on capital %22.2-19.8 -112.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,6101,463 110.0%  
From Investments Rs m687-449 -152.9%  
From Financial Activity Rs m-2,6774,292 -62.4%  
Net Cashflow Rs m-3805,306 -7.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.71 Rs / ZAR

Compare NOVARTIS With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: J.B.CHEMICALS  ELDER PHARMA  AUROBINDO PHARMA  GSK PHARMA  ORCHID PHARMA LTD  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views On News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation (The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead (The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

My Top 3 Dividend Stocks to Buy Now (Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Smallcaps that Will Outperform in the Market Rebound (Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks (The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 23, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - WOCKHARDT COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS